Correction

Bennett, Josiah; MacGuire, Jack; Novakovic, Ena; Huynh, Huey; Jones, Keri; Gendreau, Julian; Mammis, Antonios; Abraham, Mickey

doi:10.7759/cureus.c46

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 336 articles, 21 that downloaded MAUDE data files were set aside for further analysis 11–31 . Upon manual review, 135 articles with unclear queries 32–164 and 120 with incomplete queries 165–284 were excluded. Ultimately, 60 executable queries were found 5,10,285–342 .…”

Section: Methodsmentioning

confidence: 99%

Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data

Li,

Feng,

Gong

et al. 2024

J Patient Saf

View full text Add to dashboard Cite

Objective This article aims to assess the reproducibility of Manufacturer and User Facility Device Experience (MAUDE) data-driven studies by analyzing the data queries used in their research processes. Methods Studies using MAUDE data were sourced from PubMed by searching for “MAUDE” or “Manufacturer and User Facility Device Experience” in titles or abstracts. We manually chose articles with executable queries. The reproducibility of each query was assessed by replicating it in the MAUDE Application Programming Interface. The reproducibility of a query is determined by a reproducibility coefficient that ranges from 0.95 to 1.05. This coefficient is calculated by comparing the number of medical device reports (MDRs) returned by the reproduced queries to the number of reported MDRs in the original studies. We also computed the reproducibility ratio, which is the fraction of reproducible queries in subgroups divided by the query complexity, the device category, and the presence of a data processing flow. Results As of August 8, 2022, we identified 523 articles from which 336 contained queries, and 60 of these were executable. Among these, 14 queries were reproducible. Queries using a single field like product code, product class, or brand name showed higher reproducibility (50%, 33.3%, 31.3%) compared with other fields (8.3%, P = 0.037). Single-category device queries exhibited a higher reproducibility ratio than multicategory ones, but without statistical significance (27.1% versus 8.3%, P = 0.321). Studies including a data processing flow had a higher reproducibility ratio than those without, although this difference was not statistically significant (42.9% versus 17.4%, P = 0.107). Conclusions Our findings indicate that the reproducibility of queries in MAUDE data-driven studies is limited. Enhancing this requires the development of more effective MAUDE data query strategies and improved application programming interfaces.

show abstract

Section: Methodsmentioning

confidence: 99%

Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data

Li,

Feng,

Gong

et al. 2024

J Patient Saf

View full text Add to dashboard Cite

show abstract

“…Given this prolonged course of progressive neuronal loss, strategies to reduce the rate of neuronal loss or dysfunction (i.e., clinical neuroprotection or disease modification) are particularly important in treating this disorder. [3][4][5][6] Sequential testing of single agents is no longer considered the best approach to expeditiously reducing disability from PD, as many potential neuroprotective interventions are currently available. Clinical trial designs in which several agents are compared to a single control group have the advantage of participant acceptance because:  Assignment to control is less likely and,  Because of the reduced possibility of comparing the active interventions directly.…”

Section: Introductionmentioning

confidence: 99%

“…As a drug, it is used in treating PD and dopamine-responsive dystonia. 6,[12][13][14][15][16][17] L-DOPA has been the most effective treatment.…”

Section: Introductionmentioning

confidence: 99%

Centering prayer in the treatment of Parkinson's disease preliminary quality-of-life research

Machado¹,

Chinchilla²,

Machado³

et al. 2022

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Parkinson's Disease (PD) affects nearly a million Americans, a number that will increase over the coming decades. L-DOPA has been the most effective treatment. While available medical therapies help control symptoms during the initial years following diagnosis, higher doses are required over time, increasing side effects and decreasing control of symptoms. As a result, patients suffering from PD become refractory to conventional treatments. The authors anecdotally observed a significant symptom reduction in a patient who practiced Centering Prayer (CP), taught by Hesse. As a last choice, the experience led the authors to apply teaching CP to four current patients to improve their quality of life. We studied these patients before and after practicing CP, assessing tremors by electromyography records and applying the Unified Parkinson's Disease Rating Scale (UPDRS). A control group of four PD patients with high UPDRS, who were not trained in CP, were also selected. During the active phase of PD symptoms, electromyography (EMG) testing was conducted before and 30 minutes after the CP session in the test group. EMG testing was also done on the control group during the active phase of symptoms, and the groups were compared for a reduction in EMG amplitude. All patients showed a significant reduction in EMG amplitude after the CP session. There were significant UPDRS score decrements at 30 and 45 minutes, lasting up to 60 minutes. These important clinical and EMG results were not found in the control group. With these results, our group plans to collect greater samples of PD patients for proposing CP practice as an alternative treatment for this Disease.

show abstract

Developments in the mechanistic understanding and clinical application of deep brain stimulation for Parkinson’s disease

Bove

Genovese

Moro

2022

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Correction

Cited by 3 publications

References 0 publications

Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data

Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data

Centering prayer in the treatment of Parkinson's disease preliminary quality-of-life research

Developments in the mechanistic understanding and clinical application of deep brain stimulation for Parkinson’s disease

Contact Info

Product

Resources

About